<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292314</url>
  </required_header>
  <id_info>
    <org_study_id>TQ/Omega-3 on Thalassemia</org_study_id>
    <nct_id>NCT04292314</nct_id>
  </id_info>
  <brief_title>Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia</brief_title>
  <official_title>Impact of Combination Therapy Between Hydroxy Urea, Omega 3, Nigella Sativa and Honey on Antioxidant-oxidant Status and Reduction of Iron Overload in Pediatric Major Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maternity and Children Hospital, Makkah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of clinical pharmacy, faculty of pharmacy, Beni-suef univeristy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beni-Suef Health insurance hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>College of Pharmacy,Department of Pharmacy Practice,University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is evaluating the strength of combination therapy of hydroxy
      urea, omega 3, nigella sativa and honey on antioxidant-oxidant status (OXIDATIVE STRESS) in
      response to reactive oxygen species production (LIPID PEROXIDATION) and their effect on iron
      intoxication (IRON CHELATION) in pediatric major thalassemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is
      the iron-containing protein in red blood cells that carries oxygen to cells throughout the
      body. In people with beta thalassemia, low levels of hemoglobin lead to a lack of oxygen in
      many parts of the body. Affected individuals also have a shortage of red blood cells
      (anemia), which can cause pale skin, weakness, fatigue, and more serious complications.
      People with beta thalassemia are at an increased risk of developing abnormal blood clots.
      Beta thalassemia is classified into two types depending on the severity of symptoms:
      thalassemia major (also known as Cooley's anemia) and thalassemia intermedia. Of the two
      types, thalassemia major is more severe.

      Beta-thalassemia syndromes are a group of hereditary blood disorders. It is characterized by
      reduced beta globin chain synthesis, resulting in reduced Hb in red blood cells (RBC),
      decreased RBC production and anemia.

      Homozygotes for beta-thalassemia may develop either thalassemia major or thalassemia
      intermedia. Individuals with thalassemia major usually come to medical attention within the
      first 2 years and require regular blood transfusion to survive.

      Affected infants with thalassemia major fail to thrive and become progressively pale. Feeding
      problems, diarrhea, irritability, recurrent bouts of fever, and enlargement of the abdomen,
      caused by splenomegaly, may occur. If a regular transfusion program that maintains a minimum
      Hb concentration of 95-105 g/L is initiated, then growth and development are normal until the
      age of 10-11 years. After the age of 10-11 years, affected individuals are at risk of
      developing severe complications related to posttransfusional iron overload, depending on
      their compliance with chelation therapy.

      Complications of iron overload include growth retardation and failure of sexual maturation
      and also those complications observed in adults with hemachromatosis -associated hereditary
      hemochromatosis (HH): involvement of the heart (dilated myocardiopathy and pericarditis),
      liver (chronic hepatitis, fibrosis, and cirrhosis), and endocrine glands (resulting in
      diabetes mellitus and insufficiency of the parathyroid, thyroid, pituitary, and, less
      commonly, adrenal glands).

      The underlying basis of b-thalassemia pathology is the diminished b-globin synthesis leading
      to a-globin accumulation and premature apoptotic destruction of erythroblasts, causing
      oxidative stress-induced ineffective erythropoiesis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Four experimental groups, one control group.
Each experimental group receives different experimental treatments plus traditional treatment in the hospital and the control group receives only traditional treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>F 2 -isoprostanes pg/mL</measure>
    <time_frame>3 months</time_frame>
    <description>plasma F 2 -isoprostanes Picograms Per Millilitre measured by high pressure liquid chromatography assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol Mg/dl</measure>
    <time_frame>10 months</time_frame>
    <description>Total cholesterol milligrams per deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL cholesterol Mg/dl</measure>
    <time_frame>10 months</time_frame>
    <description>HDL cholesterol milligrams per deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL cholesterol Mg/dl</measure>
    <time_frame>10 months</time_frame>
    <description>LDL cholesterol milligrams per deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides Mg/dl</measure>
    <time_frame>10 months</time_frame>
    <description>Triglycerides milligrams per deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum total iron mcg/dL</measure>
    <time_frame>10 months</time_frame>
    <description>Serum total iron micrograms per decilitre</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% transferrin saturation</measure>
    <time_frame>10 months</time_frame>
    <description>transferrin saturation percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein mg/L</measure>
    <time_frame>10 months</time_frame>
    <description>C-reactive protein milligrams per deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Ferritin ng/ml</measure>
    <time_frame>10 months</time_frame>
    <description>Serum Ferritin Nanograms per milliliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Iron Binding Capacity (TIBC) mcg/dL</measure>
    <time_frame>10 months</time_frame>
    <description>Total Iron Binding Capacity micrograms per decilitre</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hemoglobin (Hbg) g/dL</measure>
    <time_frame>10 months</time_frame>
    <description>hemoglobin (Hbg) gram/deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mean corpuscular hemoglobin (MCH) pg/ml</measure>
    <time_frame>10 months</time_frame>
    <description>mean corpuscular hemoglobin (MCH) Picograms Per Millilitre</description>
  </primary_outcome>
  <primary_outcome>
    <measure>leukocytes count Î¼l</measure>
    <time_frame>10 months</time_frame>
    <description>leukocytes in microliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% Chelation activity Fe+++ - thymoquinone complex</measure>
    <time_frame>3 months</time_frame>
    <description>Chelation activity of Ferric - thymoquinone complex in percentage measured by high pressure liquid chromatography coupled with gaschromatography - mass spectroscopy analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% Chelation activity Fe++ - thymoquinone complex</measure>
    <time_frame>3 months</time_frame>
    <description>Chelation activity of Ferrous - thymoquinone complex in percentage measured by high pressure liquid chromatography coupled with gaschromatography- mass spectroscopy analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactic acid dehydrogenase U/L</measure>
    <time_frame>10 months</time_frame>
    <description>Lactic acid dehydrogenase unit per litter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reticulocyte count %</measure>
    <time_frame>10 months</time_frame>
    <description>Reticulocyte count percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hb-F level g/dL</measure>
    <time_frame>10 months</time_frame>
    <description>hemoglobin- F level in gram per deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reticulocyte absolute count</measure>
    <time_frame>10 months</time_frame>
    <description>Reticulocyte absolute count in a cubic milliliter of blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>White blood cells count</measure>
    <time_frame>10 months</time_frame>
    <description>White blood cells count in a cubic milliliter of blood</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Iron Overload</condition>
  <condition>Oxidative Stress</condition>
  <condition>Thalassemia Major</condition>
  <arm_group>
    <arm_group_label>Omega-3 experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA &amp; 200-300mg DHA) per day for 8 consecutive months up to 10 months.
in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nigella sativa experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients from each participating hospital that will receive Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months.
in addition to experimental treatment this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods till efficacy of experimental treatment proved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxyurea experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients from each participating hospital that will receive hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natural honey experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients from each participating hospital that will receive natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
in addition to the experimental treatment, this group will receive the traditional treatment of deferoxamine/deferasirox plus regular blood transfusion with dose de-escalation methods until the efficacy of experimental treatment proved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ordinary hospital treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients from each participating hospital that will receive the ordinary treatment of iron chelator agent of deferoxamine or deferasirox (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
in addition to iron chelator agent, this group receive regular blood transfusion session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3</intervention_name>
    <description>Omega-3 supplementation (300-400mg EPA &amp; 200-300mg DHA) per day for 8 consecutive months up to 10 months</description>
    <arm_group_label>Omega-3 experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nigella Sativa Oil</intervention_name>
    <description>Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months</description>
    <arm_group_label>Nigella sativa experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <description>hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.</description>
    <arm_group_label>Hydroxyurea experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Honey</intervention_name>
    <description>Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.</description>
    <arm_group_label>Natural honey experimental group</arm_group_label>
    <other_name>Natural honey formulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferoxamine</intervention_name>
    <description>deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.</description>
    <arm_group_label>Hydroxyurea experimental group</arm_group_label>
    <arm_group_label>Natural honey experimental group</arm_group_label>
    <arm_group_label>Nigella sativa experimental group</arm_group_label>
    <arm_group_label>Omega-3 experimental group</arm_group_label>
    <arm_group_label>Ordinary hospital treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood transfusion session</intervention_name>
    <description>Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.</description>
    <arm_group_label>Hydroxyurea experimental group</arm_group_label>
    <arm_group_label>Natural honey experimental group</arm_group_label>
    <arm_group_label>Nigella sativa experimental group</arm_group_label>
    <arm_group_label>Omega-3 experimental group</arm_group_label>
    <arm_group_label>Ordinary hospital treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any case with full manifestation of Î²-THALASSEMIA major disease

          2. #Aged from 7-15 years old

          3. # accompanied with ineffective erythropoiesis

          4. # with low hemoglobin level

          5. # with iron overload

        Exclusion Criteria:

          1. The presence of any other chronic illness.

          2. Patient age&gt;15 years old or &lt; 7 years old.

          3. The presence of concomitant myocardial infarction, stroke, acute chest syndrome.

          4. The patient suffers from any other type of anemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>IVO IBRAHAM [Prof of Pharmacy, Clinical Translational Sciences], Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Arizona, College of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>AHMED A ALBERRY [Assistant prof of clinical pharmacology], Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Beni-Suef University, Faculty of medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>RAGHDA R SAYED [Lecturer of Clinical Pharmacy], Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Beni-Suef University, Faculty of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MOHAMED M ABDELWAHAB GAMALELDIN, Ph.D Student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beni-Suef University, Faculty of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed H Meabad [Prof of Pediatrics], M.D</last_name>
    <role>Study Director</role>
    <affiliation>Beni-Suef university, Faculty of medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed F Mahmoud Hussein, MS.c</last_name>
    <role>Study Director</role>
    <affiliation>Beni-Suef Health insurance hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of medicine, Beni-suef univeristy - Beni-Suef university hospital</name>
      <address>
        <city>BanÄ« Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Pharmacy, Beni-Suef university</name>
      <address>
        <city>BanÄ« Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health insurance hospital</name>
      <address>
        <city>BanÄ« Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternity and Children hospital</name>
      <address>
        <city>Mecca</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Mohamed Medhat Abdelwahab Gamaleldin</investigator_full_name>
    <investigator_title>Dr.Mohamed Medhat Abdelwahab Gamaleldin</investigator_title>
  </responsible_party>
  <keyword>thymoquinone</keyword>
  <keyword>omega3</keyword>
  <keyword>hydroxyurea</keyword>
  <keyword>pediatric Thalassemia Major</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>iron chelation</keyword>
  <keyword>iron overload</keyword>
  <keyword>chelation activity of thymoquinone</keyword>
  <keyword>antioxidant effect of omega3</keyword>
  <keyword>anti-hemolysis effect of hydroxyurea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Deferoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

